Kronik Obstrüktif Akciğer Hastalığı (KOAH) Atak Tanı ve Tedavisi

Authors

Muhammed Semih Gedik
Arif Aksu

Synopsis

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and irreversible airway limitation condition resulting from an abnormal inflammatory response of the lungs to harmful particles and gases. Chronic bronchitis and emphysema are present in the vast majority of disease cases, with smoking being the primary risk factor. Other causes include occupational exposures, air pollution, and childhood infections. While emphysema features decreased lung elasticity, inability to effectively expel air during expiration, and a barrel chest appearance, chronic bronchitis is characterized by increased mucus secretion and chronic productive cough lasting for at least two years. A COPD exacerbation (attack) is an acute intensification of the patient's cough, sputum, and dyspnea symptoms, most commonly triggered by respiratory tract infections. During an exacerbation, tachypnea, use of accessory respiratory muscles, cyanosis, hypoxemia, and respiratory acidosis are observed in patients. In the differential diagnosis, emergency conditions such as asthma, heart failure, pulmonary embolism, and pneumonia must be considered. The first stage of treatment consists of removing exposure to smoking and irritants. In emergency management, patients undergo airway, breathing, and circulation (ABC) evaluation, along with cardiac monitoring and arterial blood gas analysis. If oxygen saturation is below 90%, intermittent oxygen support is administered to achieve a target saturation in the 90-98% range. In medical therapy, beta-2 agonists (salbutamol) are the first-line choice, with anticholinergic agents (ipratropium bromide), corticosteroids (prednol), theophylline, and antibiotics in the presence of infection added to the treatment. In severe cases, non-invasive or invasive mechanical ventilation support is applied.

References

Kocabaş A, Umut S, Erdinç E. (2000). Kronik Obstrüktif Akciğer Hastalığı. Turgut yayıncılık

Umut S. (2008). Toplumdan Edinilmiş Enfeksiyonlara Pratik Yaklaşımlar Sempozyum Dizisi No:61; 117-128. İstanbul Üniv. Cerrahpaşa Tıp Fak.

Umut S, Yıldırım N. (2005). Kronik Obstrüktif Akciğer Hastalığı, Istanbul. Turgut Yayıncılık.

Münevver E. İnci G. (2011). KOAH ile Yaşam. Ankara: Sağlık Bakanlığı. Yayın No: 866.

Global Initiative For Chronic Obstructive Lung Disease. Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop Report. U.S. Department of Health and Human Services. Public Health service. National Institutes of Health. National Heart, Lung, and Blood Institute. Updated: 2006.

O’Byrne PM, Postma DS. The Many Faces of Airway Inflamation. Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1999; 159: 41–66.

Nur hayat Y. (2013) Klinik Gelişim: Birinci Basamakta Göğüs Hastalıkları: KOAH. Cilt:26, Sayı:1;45-54. İstanbul: İstanbul Tabip Odası Yayınları

Said S E, Fikret K, Ali Ü. Akut Atak, Stabil KOAH ve Kor Pulmonale Hastalarında ADMA, Arjinin ve NO Düzeylerinin Belirlenmesi. Selçuk Tıp Derg 2010; 26(1):9-13

Rodriquez-Roisin R. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2013; 187:347-365.

Aaron SD, Valdemheem KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone, salmeterol for treatment of COPD: a randomized trial. Ann Intern Med 2007; 146:545-555.

Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol, fluticason propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177:19-26.

Çiledağ A, Kaya A. (2009). KOAH Alevlenmesi:30-34. Ankara: Solunum Dergisi.

Pages

21-28

Published

October 29, 2021

License

License